Fisher Scientific International Inc. announced that it has completed the acquisition of privately held Oxoid Group Holdings Limited for approximately $330 million in cash. The acquisition of Oxoid enhances Fisher's leadership position in the rapidly growing life-science market and further expands the company's proprietary-product portfolio.

Oxoid, with revenues of $155 million, is one of the world's leading manufacturers of microbiological culture media and other products that test for bacterial contamination. Oxoid's products are used in microbiology research laboratories and also in biopharmaceutical production and process validation.

Fisher Scientific expects to close on its previously announced acquisition of Dharmacon, Inc. later this month.